2-(3-diethylaminomethyl-benzoylamino)-4-methyl-5-piperidin-1-ylmethylthiophene-3-carboxylic acid ethyl ester | 773071-64-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3-diethylaminomethyl-benzoylamino)-4-methyl-5-piperidin-1-ylmethylthiophene-3-carboxylic acid ethyl ester
• 英文别名: ethyl 2-[[3-(diethylaminomethyl)benzoyl]amino]-4-methyl-5-(piperidin-1-ylmethyl)thiophene-3-carboxylate
• CAS: 773071-64-0
• 化学式: C₂₆H₃₇N₃O₃S
• 分子量: 471.664
• InChiKey: ULHBBFJOARYWAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  33
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  90.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(3-diethylaminomethyl-benzoylamino)-4-methyl-5-piperidin-1-ylmethylthiophene-3-carboxylic acid ethyl ester 在 肼 作用下， 以 乙醇 为溶剂， 反应 12.0h， 以38%的产率得到3-diethylaminomethyl-N-(3-hydrazinocarbonyl-4-methyl-5-piperidin-1-ylmethylthiophen-2-yl)-benzamide
  参考文献：
  名称：

  EP1614676

  摘要：

  公开号：
• 作为产物：
  描述：

  哌啶 、 2-(3-diethylaminomethyl-benzoylamino)-5-formyl-4-methylthiophene-3-carboxylic acid ethyl ester 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以64%的产率得到2-(3-diethylaminomethyl-benzoylamino)-4-methyl-5-piperidin-1-ylmethylthiophene-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  EP1614676

  摘要：

  公开号：

文献信息

• Compound inhibiting in vivo phosphorous transport and medicine containing the same
  申请人：Eto Nobuaki

  公开号：US20060217426A1

  公开（公告）日：2006-09-28

  An objective of the present invention is to provide compounds that can effectively suppress the concentration of phosphorus in serum to effectively prevent or treat diseases induced by an increase in concentration of phosphate in serum. The compounds according to the present invention are compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein A represents an optionally substituted five- to nine-membered unsaturated carbocyclic moiety or a five- to nine-membered unsaturated heterocyclic moiety, and represents a single bond or a double bond, R 5 represents optionally substituted aryl or the like, Z represents —N═CHR 6 R 7 or the like, R 6 and R 7 represent H, optionally substituted alkyl, optionally substituted aryl or the like, R 101 and R 102 together form ═O, and R 103 and R 104 represent H, or R 101 and R 104 together from a bond, and R 102 and R 103 together form a bond.

  本发明的目标是提供能够有效抑制血清中磷浓度的化合物，以有效预防或治疗由血清中磷酸盐浓度增加引起的疾病。本发明的化合物是由式（I）所表示的化合物及其药学上可接受的盐和溶剂化物：其中，A表示可选取的取代的五元至九元不饱和碳环状基团或五元至九元不饱和杂环状基团，表示单键或双键，R5表示可选取的取代芳基或类似物，Z表示—N═CHR6R7或类似物，R6和R7表示H、可选取的取代烷基、可选取的取代芳基或类似物，R101和R102共同形成═O，R103和R104表示H，或R101和R104共同形成键，R102和R103共同形成键。
• COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME
  申请人：Eto Nobuaki

  公开号：US20120115851A1

  公开（公告）日：2012-05-10

  An objective of the present invention is to provide compounds that can effectively suppress the concentration of phosphorus in serum to effectively prevent or treat diseases induced by an increase in concentration of phosphate in serum. The compounds according to the present invention are compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein A represents an optionally substituted five- to nine-membered unsaturated carbocyclic moiety or a five- to nine-membered unsaturated heterocyclic moiety, and represents a single bond or a double bond, R 5 represents optionally substituted aryl or the like, Z represents —N═CHR 6 R 7 or the like, R 6 and R 7 represent H, optionally substituted alkyl, optionally substituted aryl or the like, R 101 and R 102 together form ═O, and R 103 and R 104 represent H, or R 101 and R 104 together from a bond, and R 102 and R 103 together form a bond.

  本发明的目标是提供能够有效抑制血清中磷浓度的化合物，以有效预防或治疗由血清中磷酸盐浓度增加引起的疾病。本发明的化合物是由式（I）表示的化合物及其药学上可接受的盐和溶剂化物：其中，A代表可选取代的五至九元不饱和碳环基或五至九元不饱和杂环基，表示单键或双键，R5代表可选取代的芳基或类似物，Z代表—N═CHR6R7或类似物，R6和R7代表H、可选取代的烷基、可选取代的芳基或类似物，R101和R102共同形成═O，R103和R104代表H，或R101和R104共同形成键，R102和R103共同形成键。
• US8134015B2
  申请人：——

  公开号：US8134015B2

  公开（公告）日：2012-03-13
• EP1614676
  申请人：——

  公开号：——

  公开（公告）日：——